TWI455711B - 用以抑制前驅蝕骨細胞生長之醫藥組合物 - Google Patents
用以抑制前驅蝕骨細胞生長之醫藥組合物 Download PDFInfo
- Publication number
- TWI455711B TWI455711B TW100108249A TW100108249A TWI455711B TW I455711 B TWI455711 B TW I455711B TW 100108249 A TW100108249 A TW 100108249A TW 100108249 A TW100108249 A TW 100108249A TW I455711 B TWI455711 B TW I455711B
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- acceptable salt
- formula
- cellulose
- starch
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- 230000002401 inhibitory effect Effects 0.000 title claims 2
- 210000002997 osteoclast Anatomy 0.000 title 1
- 239000002243 precursor Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 3
- 229920002472 Starch Polymers 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 206010051728 Bone erosion Diseases 0.000 claims 1
- 229920002261 Corn starch Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 239000004368 Modified starch Substances 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 210000002449 bone cell Anatomy 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000004519 grease Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 239000002304 perfume Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 235000015424 sodium Nutrition 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (7)
- 一種式I化合物用於製備抑制前驅蝕骨細胞生長的醫藥組合物之用途，其係包含如式I所示之化合物及其藥學上可接受之鹽與載劑： 式I中，R1 、R3 、和R4 為氫，且R2 為乙炔。
- 如申請專利範圍第1項所述之用途，其中該載劑為賦形劑、稀釋劑、增稠劑、填充劑、結合劑、崩解劑、潤滑劑、油脂或非油脂的基劑、介面活性劑、懸浮劑、膠凝劑、輔助劑、防腐劑、抗氧化劑、穩定劑、著色劑或香料。
- 如申請專利範圍第2項所述之用途，其中該賦形劑包含微晶纖維素、聚乙烯吡咯烷酮、玉米澱粉、修飾澱粉、羧甲澱粉鈉、樹脂、糊化澱粉、糖類、聚乙二醇、聚乙烯醇、羥丙纖維素、甲基纖維素、氫氧甲基纖維素或羥丙基甲基纖維素。
- 如申請專利範圍第1項所述之用途，其中該可接受之鹽係為與無機或有機酸或鹼之生理上可接受之鹽。
- 如申請專利範圍第1項所述之用途，係為一粉末、一顆粒、一液體、一膠體或一膏體。
- 如申請專利範圍第1項所述之用途，係透過口服、經皮吸收、注射或吸入之方式進行傳輸。
- 如申請專利範圍第1項所述之用途，其係用於降低骨質蝕損作用以預防骨質疏鬆症之醫藥組合物。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW100108249A TWI455711B (zh) | 2011-03-11 | 2011-03-11 | 用以抑制前驅蝕骨細胞生長之醫藥組合物 |
| US13/180,253 US8772344B2 (en) | 2011-03-11 | 2011-07-11 | Pharmaceutical composition for inhibiting osteoclast growth |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW100108249A TWI455711B (zh) | 2011-03-11 | 2011-03-11 | 用以抑制前驅蝕骨細胞生長之醫藥組合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201236679A TW201236679A (en) | 2012-09-16 |
| TWI455711B true TWI455711B (zh) | 2014-10-11 |
Family
ID=46796098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW100108249A TWI455711B (zh) | 2011-03-11 | 2011-03-11 | 用以抑制前驅蝕骨細胞生長之醫藥組合物 |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US8772344B2 (zh) |
| TW (1) | TWI455711B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI435719B (zh) * | 2011-09-20 | 2014-05-01 | Nat Defense Medical Ct | The use of pharmaceutical compositions for the preparation of arthritis drugs |
| CN104557601B (zh) * | 2015-01-19 | 2017-01-04 | 天水师范学院 | 用于识别卤素阴离子的单体和聚合物以及制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1352650A1 (en) * | 2000-12-18 | 2003-10-15 | Institute of Medicinal Molecular Design, Inc. | Inhibitors against the production and release of inflammatory cytokines |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5905090A (en) * | 1998-04-29 | 1999-05-18 | Italfarmaco S.P.A. | Analogues of the active metabolite of leflunomide |
| WO2006132583A1 (en) * | 2005-06-07 | 2006-12-14 | Innate Pharmaceuticals Ab | Method and means for preventing and inhibiting respiratory disease, atherosclerosis and osteoporosis caused by chlamydia pneumoniae infection |
-
2011
- 2011-03-11 TW TW100108249A patent/TWI455711B/zh active
- 2011-07-11 US US13/180,253 patent/US8772344B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1352650A1 (en) * | 2000-12-18 | 2003-10-15 | Institute of Medicinal Molecular Design, Inc. | Inhibitors against the production and release of inflammatory cytokines |
Also Published As
| Publication number | Publication date |
|---|---|
| US20120232105A1 (en) | 2012-09-13 |
| TW201236679A (en) | 2012-09-16 |
| US8772344B2 (en) | 2014-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010047612A5 (zh) | ||
| MX346879B (es) | Formulaciones de ketorolaco listas para su uso. | |
| HRP20140780T4 (hr) | Amorfni i kristalinični oblik genz 112638 hemitartrata kao inhibitor glukozilceramid sintaze | |
| TN2012000246A1 (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| JP2012255026A5 (zh) | ||
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| WO2008144730A3 (en) | Stable pharmaceutical formulation for a dpp-iv inhibitor | |
| JP2013518107A5 (zh) | ||
| JP2013542247A5 (zh) | ||
| HRP20200255T1 (hr) | Formulacija ac220 osušena raspršivačem | |
| NZ612686A (en) | Sublingual films | |
| JP2012502037A5 (zh) | ||
| WO2012035559A3 (en) | Sustained release pharmaceutical compositions comprising pregabalin | |
| MX2009011554A (es) | Preparacion solida estable conteniendo un derivado de 4,5-epoximorfinano. | |
| JP2009537554A5 (zh) | ||
| MX2010009395A (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos. | |
| PH12012501965A1 (en) | Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan | |
| NZ628993A (en) | Pharmaceutical formulations comprising ccr3 antagonists | |
| WO2011037976A3 (en) | Pramipexole pharmaceutical formulations | |
| NZ596820A (en) | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid | |
| JP2012508256A5 (zh) | ||
| MX345544B (es) | Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba). | |
| TR201001417A1 (tr) | Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu | |
| TWI455711B (zh) | 用以抑制前驅蝕骨細胞生長之醫藥組合物 | |
| WO2009008004A3 (en) | Sustained release formulations of divalproex sodium |